All objectives are listed in section 3 of the protocol, but the primary objective is to demonstrate that RAP-219 is effective in reducing frequency of RNS- recorded long episodes in participants with focal onset seizures. The primary endpoint is the change in RNS long episode frequency during the second 4-week interval of the treatment period (Weeks 5-8) compared to baseline frequency (frequency per 28 days determined across 8-week retrospective and 4-week prospective baseline intervals). This is found in section 3 of the protocol. There is only one primary outcome variable, there is no secondary outcome variable. However, there are secondary objectives, each with secondary endpoints/outcome variables, which can be found in section 3 of the protocol.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: - 99 Years
• Gender: All